This biological function might be attributed to targeting Mcl-1 and DPYD. Because of its low level of expression in HCC cells, miR-302b will be a potential candidate molecular to improve the efficiency of chemotherapy in the treatment of advanced HCC patients after development of better gene delivery systems. Here, MCL1 is linked to hepatocellular carcinoma.